|Savient Pharmaceuticals, Inc.|
400 Crossing Boulevard
United States - Map
|Full Time Employees:||122|
On May 30, 2014, Savient Pharmaceuticals, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company in the United States. It engages in developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient Pharmaceuticals, Inc. sells its products through a network of specialty and wholesale distributors. The company was formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in Bridgewater, New Jersey.
No officers available for SVNTQ